Soligenix (SNGX) Metrics: History & Chart

Soligenix, Inc.(SNGX)

Biotechnology · Princeton, NJ

$0.36-0.00 (-0.28%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Soligenix, Inc.

Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma. This segment also includes SGX942, an innate defense regulator technology currently undergoing Phase III trials for various inflammatory conditions, notably oral mucositis in patients with head and neck cancer. Additionally, this division is pursuing proprietary oral formulations of beclomethasone 17,21-dipropionate designed to prevent or treat severe inflammatory gastrointestinal disorders, such as SGX203 for pediatric Crohn's disease. Another candidate, SGX302, is currently in Phase I/II clinical development for addressing mild-to-moderate psoriasis. The Public Health Solutions segment is dedicated to developing several critical assets. These include RiVax, a vaccine candidate against ricin toxin, which has successfully completed Phase Ia and Ib clinical evaluations; SGX943, a therapeutic agent in pre-clinical studies aimed at combating antibiotic-resistant and emerging infectious diseases; ThermoVax, an early-stage technology focused on enhancing vaccine thermostability; and CiVax, a pre-clinical vaccine candidate intended for COVID-19 prevention. Soligenix, Inc. was originally established as DOR BioPharma, Inc. before adopting its current name in 2009. Founded in 1987, the company maintains its corporate headquarters in Princeton, New Jersey.

Princeton, NJ

14 employees

www.soligenix.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Christopher J. Schaber

View full financials

Third-Party DCF Estimate (FMP)	$1.27
Price Gap vs Third-Party Estimate	+252.65%

7D Total Return	-4.55%
30D Total Return	-4.55%
YTD Total Return	-73.25%
1Y Total Return	-73.91%
3Y Total Return	-96.06%
5Y Total Return	-99.85%
10Y Total Return	-99.98%
15Y Total Return	-99.98%
20Y Total Return	-100.00%

2026	-73.25%
2025	-50.32%
2024	-77.72%
2023	-88.82%
2022	-31.55%
2021	-48.41%
2020

CAGR TTM	-73.75%
CAGR 3Y	-65.97%
CAGR 5Y	-72.72%
CAGR 10Y	-57.62%
CAGR 15Y	-43.58%
CAGR 20Y	-40.83%

PE Ratio	33.80
PE Ratio Avg TTM	56.51
PE Ratio Avg 3Y	56.51
Current VS TTM Avg	-40.19%
Current VS 3Y Avg	-40.19%
Current VS 5Y Avg	-40.19%

All Metrics

SNGX Valuation Metrics

SNGX Stock Price Metrics

SNGX Dividend Metrics

SNGX Growth Rate Metrics

SNGX Discounted Cash Flow Metrics

SNGX Returns By Period

SNGX Yearly Returns

SNGX Average Annual Returns By Period (CAGR)

SNGX Revenue Metrics

SNGX PE Ratio Metrics

SNGX PS Ratio Metrics

SNGX PB Ratio Metrics

SNGX Price to Free Cash Flow Ratio Metrics

SNGX Debt to Equity Ratio Metrics

SNGX PEG Ratio Metrics

SNGX FCF Yield

SNGX Earnings Yield

SNGX EBITDA Yield

SNGX OCF Yield

SNGX EV/EBIT Ratio Metrics

SNGX EV/EBITDA Ratio Metrics

SNGX EV/Assets Ratio Metrics

SNGX EV/Sales Ratio Metrics

SNGX Current Ratio Metrics

SNGX Quick Ratio Metrics

SNGX ROIC Metrics

SNGX Return on Assets Metrics

SNGX Return on Equity Metrics

SNGX Net Profit Margin Metrics

SNGX Gross Profit Margin Metrics

SNGX Tax Rate Metrics

PS Ratio	42.53
PS Ratio Avg TTM	41.64
PS Ratio Avg 3Y	161.30
Current VS TTM Avg	+2.13%
Current VS 3Y Avg	-73.63%
Current VS 5Y Avg	+22.56%

PB Ratio	0.86
PB Ratio Avg TTM	0.93
PB Ratio Avg 3Y	1.38
Current VS TTM Avg	-7.56%
Current VS 3Y Avg	-37.90%
Current VS 5Y Avg	-56.29%

PFCF Ratio	N/A
PFCF Ratio Avg TTM	N/A
PFCF Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Debt/Equity Ratio	0.05
Debt/Equity Ratio Avg TTM	0.10
Debt/Equity Ratio Avg 3Y	0.40
Current VS TTM Avg	-54.09%
Current VS 3Y Avg	-88.55%
Current VS 5Y Avg	-91.44%

PEG Ratio	N/A
PEG Ratio Avg TTM	N/A
PEG Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

FCF Yield	N/A
FCF Yield Avg TTM	N/A
FCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Earnings Yield	2.96%
Earnings Yield Avg TTM	1.75%
Earnings Yield Avg 3Y	1.75%
Current VS TTM Avg	+69.11%
Current VS 3Y Avg	+69.11%
Current VS 5Y Avg	+69.11%

EBITDA Yield	N/A
EBITDA Yield Avg TTM	N/A
EBITDA Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

OCF Yield	N/A
OCF Yield Avg TTM	N/A
OCF Yield Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebit Ratio	N/A
Ev/Ebit Ratio Avg TTM	N/A
Ev/Ebit Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Ebitda Ratio	N/A
Ev/Ebitda Ratio Avg TTM	N/A
Ev/Ebitda Ratio Avg 3Y	N/A
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Ev/Assets Ratio	0.28
Ev/Assets Ratio Avg TTM	0.47
Ev/Assets Ratio Avg 3Y	0.12
Current VS TTM Avg	-40.43%
Current VS 3Y Avg	+136.08%
Current VS 5Y Avg	-40.21%

Ev/Sales Ratio	2.35
Ev/Sales Ratio Avg TTM	2.64
Ev/Sales Ratio Avg 3Y	161.09
Current VS TTM Avg	-11.04%
Current VS 3Y Avg	-98.54%
Current VS 5Y Avg	-84.59%

Current Ratio	2.77
Current Ratio Avg TTM	2.32
Current Ratio Avg 3Y	2.00
Current VS TTM Avg	+19.18%
Current VS 3Y Avg	+38.28%
Current VS 5Y Avg	+33.38%

Quick Ratio	2.77
Quick Ratio Avg TTM	2.32
Quick Ratio Avg 3Y	2.00
Current VS TTM Avg	+19.18%
Current VS 3Y Avg	+38.28%
Current VS 5Y Avg	+33.38%

ROIC	(161.69%)
ROIC Avg 3Y	(179.56%)
ROIC Avg 5Y	(142.20%)
Current VS 3Y Avg	+9.96%
Current VS 5Y Avg	-13.70%
Current VS 10Y Avg	+4.01%

ROA	(97.52%)
ROA Avg TTM	(32.08%)
ROA Avg 3Y	(25.95%)
Current VS TTM Avg	-203.97%
Current VS 3Y Avg	-275.85%
Current VS 5Y Avg	-375.59%

ROE	(154.08%)
ROE Avg TTM	(291.24%)
ROE Avg 3Y	(205.95%)
Current VS TTM Avg	+47.10%
Current VS 3Y Avg	+25.19%
Current VS 5Y Avg	+21.08%

Net Profit Margin	0.00%
Net Profit Margin Avg TTM	0.00%
Net Profit Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Gross Profit Margin	0.00%
Gross Pft Margin Avg TTM	0.00%
Gross Pft Margin Avg 3Y	0.00%
Current VS TTM Avg	N/A
Current VS 3Y Avg	N/A
Current VS 5Y Avg	N/A

Tax Rate	0.00%
Tax Rate Avg 3Y	(162.98%)
Tax Rate Avg 5Y	(74.02%)
Current VS 3Y Avg	+100.00%
Current VS 5Y Avg	+100.00%
Current VS 10Y Avg	+100.00%